Janssen submits Genmab-developed drug for EMA approval
Shortly after applying for US marketing approval for drug candidate teclistamab, which is based on Genmab’s duobody platform, the US-based pharmaceutical firm has followed this up with a European application with the EMA.
by ULRICH QUISTGAARD, translated by daniel pedersen
The European Medicines Council (EMA) has just received a new marketing authorization application for teclistamab, a treatment for relapsed or refractory multiple myeloma, which is a type of bone marrow cancer.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novartis increases sales of Genmab-developed sclerosis drug
For subscribers
